Has Prakash Peddi, MD received payments from drug or device companies?

Yes. Drug and device makers reported $670,312 in general payments to Prakash Peddi, MD across 1,224 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Prakash Peddi, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Prakash Peddi, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Prakash Peddi, MD

Hematology & Oncology · Shreveport, LANPI 1093926446

Payments from drug & device makers

$670,312in general payments, 2019–2025

Across 1,224 payments — averaging $547.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novartis$265K
AstraZeneca$140K
Gilead$104K
Daiichi Sankyo Inc.$69K
Stemline Therapeutics Inc.$65K
Seagen Inc.$14K
plus $14K from 54 others

$1,024in research payments, 2019–2025

Across 1 payment — averaging $1024.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eli Lilly$1K

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novartis	222	$264,720
AstraZeneca(2 entities)	133	$139,833
Gilead(2 entities)	97	$104,030
Daiichi Sankyo Inc.	153	$69,104
Stemline Therapeutics Inc.	50	$65,013
Seagen Inc.	11	$13,929
Immunomedics, Inc.	2	$1,588
Merck	61	$1,211
Johnson & Johnson(2 entities)	60	$1,211
Genentech USA, Inc.	38	$706
Eisai Inc.	21	$701
Coherus Oncology, Inc.	19	$558
Pfizer	43	$549
Astellas Pharma US Inc	17	$539
Bristol Myers Squibb	28	$538
E.r. Squibb & Sons, L.L.C.	27	$457
AbbVie	12	$373
Amgen	16	$370
Puma Biotechnology, Inc.	20	$366
EMD Serono, Inc.	18	$352
Pharmacosmos Therapeutics Inc.	12	$331
Takeda Pharmaceuticals U.S.A., Inc.	9	$297
Regeneron Healthcare Solutions, Inc.	13	$285
Tactile Systems Technology Inc	13	$278
Myriad Genetic Laboratories, Inc.	3	$235
GSK	11	$223
Sanofi	11	$206
Incyte Corporation	12	$190
Bayer	8	$182
Tempus AI, Inc	8	$179
Lilly USA, LLC	12	$177
Menarini Silicon Biosystems, Inc.	4	$141
Bard Peripheral Vascular, Inc.	1	$125
Beigene USA, Inc.	6	$120
Pharmacyclics LLC, An Abbvie Company	4	$83
Taiho Oncology, Inc.	4	$77
Eli Lilly	2	$76
AVEO Pharmaceuticals, Inc.	3	$71
Exelixis Inc.	3	$69
Acrotech Biopharma Inc.	3	$67
Pharmaessentia USA Corporation	3	$62
Mirati Therapeutics, Inc.	3	$61
Siemens Medical Solutions USA, Inc.	1	$59
Lexicon Pharmaceuticals, Inc.	1	$58
Recordati_rare_diseases_inc.	3	$56
Boehringer Ingelheim	2	$52
Dendreon Pharmaceuticals LLC	2	$40
Blueprint Medicines Corporation	2	$34
Immunocore Limited	1	$33
AMAG Pharmaceuticals, Inc.	2	$32
G1 Therapeutics, Inc.	2	$30
Tersera Therapeutics LLC	1	$28
Geron Corporation	1	$25
Karyopharm Therapeutics Inc.	1	$23
ADC Therapeutics America, Inc.	1	$22
Azurity Pharmaceuticals, Inc.	1	$20
Tesaro, Inc.	1	$20
Jazz Pharmaceuticals Inc.	1	$19
Morphosys, US Inc.	1	$18
Biocartis US, Inc	1	$16

How this compares

$670,312 in reported general payments places this provider in the 90th percentile of 183 hematology & oncology providers in Louisiana.

See all hematology & oncology providers in Louisiana →

Medicare billing

Part B allowed, 2024

$141,239

Medicare patients

502

Services billed

1,488

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Shreveport

Anil VeluvoluShreveport$915K
Gary BurtonShreveport$458K
Kevin GallagherShreveport$339K
Poornima RamadasShreveport$313K
Richard MansourShreveport$281K
Shashank CingamShreveport$271K
Maxwell McDonaldShreveport$163K
Kirtan KotichaShreveport$117K
Joyce FeaginShreveport$95K
Steven BoniolShreveport$94K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →